Zakiya Rice, MD
Dermatology · Atlanta, GANPI 1871699041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $844,089 of the $1,136,425 with a category attached, or 74.3%. 28 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 30.2% of the total. Among dermatology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,171 payments — averaging $970.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$343K
- Sanofi$275K
- Pfizer$172K
- Incyte Corporation$130K
- AbbVie$96K
- Organon$73K
- plus $48K from 22 others
Across 35 payments — averaging $1002.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$34K
- Regeneron$1K
What the payments were for
- Consulting fees$158,46614%
- Speaking & faculty fees$844,08974%
- Travel & lodging$109,97810%
- Food & beverage$23,6942%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 337 | $342,796 |
| Sanofi | 184 | $274,708 |
| Pfizer | 136 | $171,609 |
| Incyte Corporation | 135 | $130,470 |
| AbbVie(2 entities) | 164 | $96,251 |
| Organon | 59 | $73,024 |
| Dermavant Sciences, Inc. | 16 | $17,146 |
| Dermira, Inc. | 7 | $12,640 |
| Eli Lilly | 2 | $8,400 |
| LEO Pharma Inc. | 12 | $3,059 |
| Novartis | 26 | $2,577 |
| Regeneron | 4 | $1,385 |
| Galderma Laboratories, L.p. | 13 | $453 |
| Lilly USA, LLC | 20 | $449 |
| Sun Pharmaceutical Industries Inc. | 10 | $267 |
| Johnson & Johnson | 13 | $259 |
| Arcutis Biotherapeutics, Inc. | 8 | $254 |
| UCB, Inc. | 4 | $165 |
| Sanofi-aventis U.S. LLC | 5 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Mayne Pharma Commercial LLC | 4 | $72 |
| Verrica Pharmaceuticals Inc. | 2 | $49 |
| Strata Skin Sciences, Inc. | 4 | $42 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $28 |
| Botanix SB Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,136,425 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Triamcinolone Acetonide | 22 | $1,165 |
| Clobetasol Propionate | 11 | $1,022 |
| Ketoconazole | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Atlanta
- Joseph PayneAtlanta$711K
- Jamie WeismanAtlanta$620K
- Mack RachalAtlanta$260K
- Sumayah TaliaferroAtlanta$104K
- Sarah ChisolmAtlanta$59K
- Anna PareAtlanta$58K
- Lauren OrensteinAtlanta$52K
- Chelsie RogersAtlanta$43K
- Ron FeldmanAtlanta$29K
- Christine LawAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.